7 results about "Fat mass" patented technology

The present invention relates to the use of an s100a8 / a9 and complement 3 inhibitor in the preparation of a drug for treating or preventing cachexia. The treatment or prevention of cachexia comprises increasing the body weight, lean body mass and fat mass, and increasing food intake in a cachectic subject, or preventing fat mass consumption, slowing the rate of body weight loss, the rate of fat mass loss and the rate of lean body mass loss, counteracting anorexia, muscle strength loss, fatigue and body weight loss, or improving abnormal biochemical results. Provided is a new understanding for the mechanism of energy balance regulation in cancer cachexia, with an emphasis on the effects of S100a8 / a9 and C3 in cancer cachexia. The inhibition of S100a8 / a9 and complement 3 can promote fat recovery and increase food intake. Particularly, it is verified that an S100a8 / a9 inhibitor can prevent body weight loss, especially adipose tissue loss, in a cachectic subject, and significantly increases food intake in the subject.

Provided herein are methods of treating, preventing, or reducing conditions and / or side effects associated with anti-cancer agents (e.g., chemotherapeutic agents) via administration of a non-naturally occurring melanocortin analog prior to, during, and / or after administration of the anti-cancer agents. The methods reduce adverse effects associated with the anti-cancer agent, such as anorexia, weight loss, muscle mass loss, fat mass loss, wasting, reduced appetite, and loss of appetite, thereby enhancing tolerance of the anti-cancer agents and survival of the subject having cancer or having a disease or condition that is not cancer but is treated, reduced, or prevented by administration of an anti-cancer agent.

This invention relates to the use of S100a8 / a9 and complement 3 inhibitors in the preparation of medicaments for the treatment or prevention of cachexia, wherein the treatment or prevention of cachexia involves increasing the body weight, lean body mass, fat mass, and food intake of cachectic subjects, or preventing fat loss, slowing the rate of weight loss, slowing the rate of fat mass loss, slowing the rate of lean body mass loss, resisting anorexia, resisting muscle weakness, resisting fatigue, resisting weight loss, and improving abnormal biochemical results. This invention provides a new understanding of the mechanism of energy balance regulation in cancer cachexia, focusing on the roles of S100a8 / a9 and C3 in cancer cachexia. This invention finds that inhibiting S100a8 / a9 and complement 3 can promote fat recovery and increase food intake. In particular, it demonstrates that S100a8 / a9 inhibitors can prevent the loss of body weight, especially adipose tissue, in cachectic subjects and significantly increase their food intake.

The present invention is based on the realization and verification that inhibition of Luteinizing hormone (LH) and / or luteinizing hormone / choriogonadotropin receptor (LHCGR) is useful in the treatment, alleviation or prevention of different medical states related to perimenopause and menopause in women or hypogonadism in men. Thus, an aspect of the present invention relates to LH and / or LHCGR inhibitors for use in the treatment of postmenopausal osteoporosis in a female subject. Another aspect relates to LH and / or LHCGR inhibitors for use in the reduction of fat mass in a postmenopausal female subject. A further aspect relates to LH and / or LHCGR inhibitors for use in the treatment, hypergonadotropic hypogonadism in a male subject. In addition, another aspect relates to LH and / or LHCGR inhibitors for use in the treatment of symptoms of perimenopause and / or postmenopause such as hot flashes, night sweats, osteoporosis, weight gain, hypothyroidism, conversion of T4 to T3, and / or primary hyperparathyroidism.

The present invention provides a sugar-restricted, high-fat diet for improving liver disease. In the sugar-restricted, high-fat diet, daily fat intake may be set at 120 g or more based on a real body weight of 50 kg or set at an amount corresponding to 70% or more of the total daily energy intake. The sugar-restricted, high-fat diet can reduce body fat mass and AST, ALT, and γ-GTP levels in nonalcoholic fatty liver disease patients.

The application provides a brown fat recognition method and recognition device based on plain CT images, and solves the technical problem that the recognition cost and recognition accuracy of the existing brown fat recognition cannot be matched. The method comprises the following steps: establishing a tissue feature recognition model of brown fat by using the image features of the brown fat in the plain CT image resources; identifying the brown fat in the to-be-detected plain CT image according to the tissue feature recognition model, and quantifying the physical properties of the brown fat. The tissue feature recognition model is mainly trained or optimized by using low-cost plain CT image data, so that the brown fat and white fat can be effectively distinguished. The application provides a basic tool for target point recognition and tissue quantification, so as to explore how to activate the brown fat tissue in the human body through drugs, nutrition and other means, and to expect to find new strategies for treating obesity and diabetes.

This application relates to compositions comprising polar lipids for maintaining or increasing mobility and vitality. In particular, the invention relates to the use of milk fat globule membrane materials comprising one or more polar lipids in the manufacture of compositions or pharmaceuticals intended for (a) maintaining or increasing lean muscle mass and / or maintaining or decreasing fat mass in human subjects; (b) increasing daily activity and reducing sedentary time in human subjects; and / or (c) after daily administration of the composition or pharmaceuticals for a period of at least three or four months, and wherein the human subjects exercise at least two days per week, compared to the sedentary time and / or low-intensity physical activity time prior to the commencement of daily administration of the composition or pharmaceuticals, a reduction of at least 7 minutes per day in sedentary time and / or an increase of at least 3 minutes per day in low-intensity physical activity time in human subjects.